257 related articles for article (PubMed ID: 33071070)
1. Glutamate in schizophrenia: Neurodevelopmental perspectives and drug development.
Egerton A; Grace AA; Stone J; Bossong MG; Sand M; McGuire P
Schizophr Res; 2020 Sep; 223():59-70. PubMed ID: 33071070
[TBL] [Abstract][Full Text] [Related]
2. Targeting glutamate system for novel antipsychotic approaches: relevance for residual psychotic symptoms and treatment resistant schizophrenia.
de Bartolomeis A; Sarappa C; Magara S; Iasevoli F
Eur J Pharmacol; 2012 May; 682(1-3):1-11. PubMed ID: 22387855
[TBL] [Abstract][Full Text] [Related]
3. The glutamate hypothesis of schizophrenia: neuroimaging and drug development.
Egerton A; Stone JM
Curr Pharm Biotechnol; 2012 Jun; 13(8):1500-12. PubMed ID: 22283750
[TBL] [Abstract][Full Text] [Related]
4. New Pharmacological Targets for the Treatment of Schizophrenia: A Literature Review.
Ventriglio A; Bellomo A; Ricci F; Magnifico G; Rinaldi A; Borraccino L; Piccininni C; Cuoco F; Gianfelice G; Fornaro M; Delle Monache S; De Berardis D
Curr Top Med Chem; 2021 Oct; 21(16):1500-1516. PubMed ID: 34218785
[TBL] [Abstract][Full Text] [Related]
5. [Evidence on the key role of the metabotrobic glutamatergic receptors in the pathogenesis of schizophrenia: a "breakthrough" in pharmacological treatment].
Pannese R; Minichino A; Pignatelli M; Delle Chiaie R; Biondi M; Nicoletti F
Riv Psichiatr; 2012; 47(2):149-69. PubMed ID: 22622251
[TBL] [Abstract][Full Text] [Related]
6. Dopamine-glutamate interaction and antipsychotics mechanism of action: implication for new pharmacological strategies in psychosis.
de Bartolomeis A; Fiore G; Iasevoli F
Curr Pharm Des; 2005; 11(27):3561-94. PubMed ID: 16248808
[TBL] [Abstract][Full Text] [Related]
7. Glutamatergic neurotransmission modulation and the mechanisms of antipsychotic atypicality.
Heresco-Levy U
Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct; 27(7):1113-23. PubMed ID: 14642971
[TBL] [Abstract][Full Text] [Related]
8. Utility of Imaging-Based Biomarkers for Glutamate-Targeted Drug Development in Psychotic Disorders: A Randomized Clinical Trial.
Javitt DC; Carter CS; Krystal JH; Kantrowitz JT; Girgis RR; Kegeles LS; Ragland JD; Maddock RJ; Lesh TA; Tanase C; Corlett PR; Rothman DL; Mason G; Qiu M; Robinson J; Potter WZ; Carlson M; Wall MM; Choo TH; Grinband J; Lieberman JA
JAMA Psychiatry; 2018 Jan; 75(1):11-19. PubMed ID: 29167877
[TBL] [Abstract][Full Text] [Related]
9. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.
Javitt DC
Int Rev Neurobiol; 2007; 78():69-108. PubMed ID: 17349858
[TBL] [Abstract][Full Text] [Related]
10. [Role of astrocytes in alterations of glutamatergic neurotransmission in schizophrenia].
Kolomeets NS
Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(1):110-117. PubMed ID: 25945378
[TBL] [Abstract][Full Text] [Related]
11. Glutamatergic transmission in schizophrenia: from basic research to clinical practice.
Kantrowitz J; Javitt DC
Curr Opin Psychiatry; 2012 Mar; 25(2):96-102. PubMed ID: 22297716
[TBL] [Abstract][Full Text] [Related]
12. Inflammation and the glutamate system in schizophrenia: implications for therapeutic targets and drug development.
Müller N
Expert Opin Ther Targets; 2008 Dec; 12(12):1497-507. PubMed ID: 19007319
[TBL] [Abstract][Full Text] [Related]
13. Significance of dysfunctional glutamatergic transmission for the development of psychotic symptoms.
Pietraszek M
Pol J Pharmacol; 2003; 55(2):133-54. PubMed ID: 12926541
[TBL] [Abstract][Full Text] [Related]
14. Glutamatergic agents for schizophrenia: current evidence and perspectives.
Zink M; Correll CU
Expert Rev Clin Pharmacol; 2015 May; 8(3):335-52. PubMed ID: 25916667
[TBL] [Abstract][Full Text] [Related]
15. Alterations in glutamatergic signaling in the brain of dopamine supersensitivity psychosis and non-supersensitivity psychosis model rats.
Oda Y; Fujita Y; Oishi K; Nakata Y; Takase M; Niitsu T; Kanahara N; Shirayama Y; Hashimoto K; Iyo M
Psychopharmacology (Berl); 2017 Oct; 234(20):3027-3036. PubMed ID: 28744562
[TBL] [Abstract][Full Text] [Related]
16. Bringing order to the glutamate chaos in schizophrenia.
Moghaddam B
Neuron; 2003 Dec; 40(5):881-4. PubMed ID: 14659087
[TBL] [Abstract][Full Text] [Related]
17. The potential role of lamotrigine in schizophrenia.
Large CH; Webster EL; Goff DC
Psychopharmacology (Berl); 2005 Sep; 181(3):415-36. PubMed ID: 16001126
[TBL] [Abstract][Full Text] [Related]
18. Imaging the glutamate system in humans: relevance to drug discovery for schizophrenia.
Stone JM
Curr Pharm Des; 2009; 15(22):2594-602. PubMed ID: 19689330
[TBL] [Abstract][Full Text] [Related]
19. Right care, first time: a highly personalised and measurement-based care model to manage youth mental health.
Hickie IB; Scott EM; Cross SP; Iorfino F; Davenport TA; Guastella AJ; Naismith SL; Carpenter JS; Rohleder C; Crouse JJ; Hermens DF; Koethe D; Markus Leweke F; Tickell AM; Sawrikar V; Scott J
Med J Aust; 2019 Nov; 211 Suppl 9():S3-S46. PubMed ID: 31679171
[TBL] [Abstract][Full Text] [Related]
20. Is the glycine site half saturated or half unsaturated? Effects of glutamatergic drugs in schizophrenia patients.
Javitt DC
Curr Opin Psychiatry; 2006 Mar; 19(2):151-7. PubMed ID: 16612195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
